Ziphius Vaccines
↗Ghent, Belgium
Ziphius Vaccines is a Belgian biopharmaceutical company founded in 2019, focused on developing next-generation vaccines and therapeutics. The company utilizes a proprietary self-amplifying RNA (saRNA) and lipid nanoparticle (LNP) platform designed to achieve higher and more prolonged protein expression at lower doses compared to conventional mRNA technologies.
The company's pipeline targets infectious diseases, rare genetic conditions, and oncology. Ziphius operates with a focus on preclinical development and has established strategic collaborations to advance its technology, including manufacturing partnerships for clinical-stage research.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:RNA Therapeutics and Vaccines
SIZE & FINANCIALS
Employees:51-200
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Late Stage VC
Total Raised:$55M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:RNA, saRNA, Lipid Nanoparticles
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Charles River Laboratories (Manufacturing collaboration for saRNA-based vaccine materials)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Juno Therapeutics, MiNA Therapeutics
LEADERSHIP
Key Executives:
Chris Cardon - CEO & Founder
Johan Van Hoof - Chief Scientific Advisor
Board Members:Jo Bury (Chair), Chris Cardon, Johan Van Hoof
LINKS
Website:ziphius.org
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ziphius Vaccines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ziphius Vaccines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.